Antiplatelet treatment does not reduce the severity of subsequent stroke

Neurology

Volumn 53, Issue 4, 1999, Pages 825-829

  Sivenius, Juhani ^d   Cunha, L ^d   Diener, H C ^d   Forbes, C ^a   Laakso, M ^d   Lowenthal, A ^b   Smets, P ^c   Riekkinen Sr , P ^d  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b Medical Research OCMW   (Belgium)

^c FREE UNIVERSITY OF BRUSSELS   (Belgium)

^d NONE

Author keywords

Antiplatelet treatment; Stroke; TIA

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; DIPYRIDAMOLE;

ARTICLE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCORING SYSTEM; STROKE; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME;

EID: 0033546974     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.53.4.825     Document Type: Article

References (15)

1. Canadian Cooperative Study Group. A randomized trial of aspirin and sulfinpyrazone in threatened stroke. N Engl J Med 1978;299:53-59.
2. Bousser MG, Eschwege E, Haguenau M, et al. "AICLA" controlled trial of aspirin and dipyridamole in the secondary prevention of atherothrombotic cerebral ischemia. Stroke 1983; 14:5-14.
3. European Stroke Prevention Study Group. European Stroke Prevention Study: principal end-points. Lancet 1987;2:1351-1354.
4. UK-TIA Study Group. The UK-TIA Aspirin Trial: the interim results. BMJ 1988;296:316-320.
5. ESPS Working Group. European Stroke Prevention Study. Stroke 1990;21:1122-1130.
6. The SALT Collaborative Group. Swedish Aspirin Low Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischemic events. Lancet 1991;338:1345-1349.
7. Antiplatelet Trialists' Collaboration Study Group. Collaborative overview of randomized trials of antiplatelet therapy: I. prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
8. Diener H, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study 2: DP and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996;143:1-13.
9. Grotta JC, Lemak NA, Gary H, Fields WS, Vital D. Does platelet antiaggregant therapy lessen the severity of stroke? Neurology 1985;35:632-636.
10. Bornstein N, Karepov VG, Aronovich BD, Gorbulev AY, Treves TA, Korczyn AD. Failure of ASA treatment after stroke. Stroke 1994;25:275-277.
11. Karepov V, Bornstein NM, Hass Y, Korczyn AD. Does daily ASA diminish severity of first-ever stroke? Arch Neurol 1997; 54:1369-1371.
12. Grilli M, Pizzi M, Memo M, Spano PF. Neuroprotection by ASA and sodium salicylate through blockade of NF-κB activation. Science 1996;274:1383-1385.
13. Bertrand-Hardy J-M, Cunha L, Forbes C, et al. European Stroke Prevention Study 2: baseline data. J Neurol Sci 1995; 131(suppl):1-58.
14. Van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJA, Van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988;19:604-607.
15. Cappelleri JC, Lau J, Kupelnick B, Chalmers TC. Efficacy and safety of different ASA dosages on vascular diseases in high-risk patients: a metaregression analysis. J Curr Clin Trials [serial online] 1995;4(174).